Edition:
United Kingdom

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

6.55USD
23 Feb 2018
Change (% chg)

$-0.25 (-3.68%)
Prev Close
$6.80
Open
$6.85
Day's High
$6.85
Day's Low
$6.45
Volume
22,583
Avg. Vol
64,615
52-wk High
$9.02
52-wk Low
$2.80

Latest Key Developments (Source: Significant Developments)

Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS.STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​.STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018.STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​.STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL.STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​.STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​.STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​.STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​.  Full Article

Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS.STRONGBRIDGE BIOPHARMA - LETTERS REQUEST INFORMATION PRINCIPALLY RELATING TO THE PRICING OF KEVEYIS, AMONG OTHER THINGS - SEC FILING.STRONGBRIDGE BIOPHARMA - CO IN THE PROCESS OF RESPONDING TO THE LETTERS.  Full Article

Strongbridge Biopharma Q3 loss per share $0.98
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.35.Q3 GAAP loss per share $0.98.Q3 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Strongbridge Biopharma Plc- ‍Recorlev (levoketoconazole) phase 3 top-line results remain on track with SONICS in Q2 2018 and LOGICS in Q4 2018​.Strongbridge Biopharma Plc- existing cash resources at Sept 30, net proceeds from Oct offering provides sufficient cash under current operating plan​.Strongbridge Biopharma Plc- ‍had pro forma cash and cash equivalents of $67.8 million as of September 30, 2017​.Strongbridge Biopharma Plc - qtrly total revenues $‍2.5 million​.  Full Article

Storebrand Asset Management reports 5.01 pct passive stake in Strongbridge Biopharma
Thursday, 29 Sep 2016 

Storebrand Asset Management:Storebrand Asset Management AS reports 5.01 pct passive stake in Strongbridge Biopharma Plc as of Sept 20 - SEC filing.  Full Article

Strongbridge Biopharma reports Q1 loss per share $0.57
Tuesday, 17 May 2016 

Strongbridge Biopharma PLC : Strongbridge Biopharma PLC reports first quarter 2016 financial results . Company believes it has sufficient existing cash and cash equivalents to fund planned operations into Q4 of 2017 . Q1 loss per share $0.57 .Q1 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Strongbridge Biopharma Announces Pricing Of Public Offering

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES